Digitalis glycosides exert both excitatory and inhibitory autonomic actions in animals and produce vasoconstriction in normal humans but produce vasodilation in heart failure patients.
Digitalis glycosides exert both excitatory and inhibitory autonomic actions in animals and produce vasoconstriction in normal humans but produce vasodilation in heart failure patients.
To determine whether or not these contrasting vascular responses are due to differing autonomic actions of the drug, we compared the responses to intravenous administration of Cedilanid-D (0.02 mg/kg) in eight normal subjects (mean age, 23+±1 years) and eight patients with moderate-to-severe heart failure (mean age, 52±5 years, NYHA Class III-IV). Hemodynamics and efferent sympathetic nerve activity to muscle (MSNA) were measured during 5-minute periods before (control) and 20 minutes after drug administration. In the heart failure patients, Cedilanid-D significantly increased systolic and pulse pressures, whereas mean arterial pressure was unchanged. There was a decrease in right atrial pressure and a tendency for a decrease in pulmonary artery diastolic pressure with a slowing of heart rate. Cardiac index increased by 24±-7%. Short-term administration of digitalis in these heart failure patients produced a fall in forearm vascular resistance (from 37.6±8.2 to 31.8± 8.1 units, p <0.05) and an early, profound, and sustained decrease in MSNA (from 831.0±118.4 to 474.4+103.6 units/ 100 heart beats, p <0.01). Digitalis glycosides produced different vascular and MSNA responses in the normal subjects. In the normal volunteers, the drug significantly increased systolic, mean, and pulse pressures and decreased central venous pressure and heart rate. Despite the significant increase in arterial pressure, there was no change in forearm vascular resistance (from 11.7+ 1.0 to 12.7+ 1.0 units, p=NS) or MSNA (from 494.8±88.5 to 369.1± 60.5 units/100 heart beats, p=NS), suggesting a sympathoexcitatory response in normal subjects. To determine whether or not the digitalis-induced sympathoinhibition in the heart failure patients was simply due to an inotropic effect (stimulation of inhibitory cardiac mechanoreceptors), we studied the responses of seven additional patients with heart failure before and during administration of dobutamine (3.4±+0.4 ,ug/kg/min). Dobutamine produced a 34±3% increase in cardiac index, no significant change in systemic arterial pressures, a decrease in pulmonary artery diastolic and right atrial pressures, and no change in heart rate or forearm vascular resistance (from 30.2 ±4.3 to 26.5 ±4.7 units, p=NS). In contrast to the sympathoinhibition seen after digitalis administration and despite comparable inotropic effects of the two agents, there was no change in MSNA during dobutamine infusion (from 527.6±112.7 to 443.7+ 95.9 units/ 100 heart beats, p=NS). These studies provide the first direct evidence that digitalis glycosides produce marked sympathoinhibitory actions in humans with heart failure, an efect that likely cannot be ascribed solely to an inotropic action of the drug. We suggest these autonomic effects result from afferent activation of low-or high-pressure baroreceptor mechanisms by digitalis in patients with heart failure. (Circulation 1989:80:65-77) 66 Circulation Vol 80, No 1, July 1989 S ince the classic treatise on foxglove by William Withering over 200 years ago,1 digitalis glycosides have been a mainstay in the treatment of heart failure. Recent prospective controlled trials suggest that digitalis produces beneficial clinical effects in patients with moderate-to-severe heart failure in sinus rhythm. 2 6 This effect has been assumed to be related to the inotropic action of the agent. However, experimental and limited clinical observations suggest that the digitalis glycosides also possess important autonomic neural actions.
Digitalis glycosides exert actions at various sites in the neurocardiovascular axis. In animals, digitalis preparations directly sensitize tonically active cardiopulmonary7,8 or arterial baroreceptors,9 augment afferent cardiopulmonary baroreflex nerve activity,'( and reflexly inhibit efferent renal sympathetic nerve activity." Detailed animal studies also show potent vasoconstrictor responses to digitalis administration in both skeletal and coronary vascular beds because of central neural or efferent sympathoexcitatory mechanisms.12-14 Direct vasoconstriction is also observed when these agents are applied to vascular smooth muscle. [15] [16] [17] In 1964, Mason and Braunwald18 reported that intravenous ouabain causes forearm arterial and venous vasoconstriction in normal subjects, whereas vasodilation is exhibited by patients with heart failure. Prior studies in our laboratory confirmed this vasodilatory response after intravenous administration of rapidly acting digitalis preparations in patients with heart failure and suggested that these agents also quickly normalize baroreflex circulatory control mechanisms. 19 To determine whether or not the differing vascular effects of digitalis in normal subjects and heart failure patients reflected differing autonomic actions of the agent, we examined hemodynamic and efferent sympathetic nerve responses after short-term administration of digitalis. We tested the hypothesis that the predominant effect of digitalis in normal humans would be sympathoexcitation whereas that in heart failure patients would be sympathoinhibition. To further define the mechanism of the autonomic action of digitalis in heart failure, we performed additional studies in a separate group of heart failure patients, which examined the autonomic effects of the equipotent nondigitalis inotropic agent dobutamine.
Methods

Human Subjects
Twenty-three human subjects were examined in three main study groups: 1) heart failure-digitalis group (n=8), 2) normal subject-digitalis group (n=8), and 3) heart failure-dobutamine group (n =7). Three additional patients with milder heart failure underwent placebo study.
No patient was studied within 1 month of a myocardial infarction. Digitalis glycosides were discontinued in any patient previously receiving them for a minimum of 7 days before study, and this was confirmed by negative findings in the serum assay for digoxin. All oral medications except for diuretics were withheld for a minimum of 4 half-lives, and diuretics were withheld for at least 12 hours before study. Intravenous inotropic support was discontinued for a minimum of 6 hours before study in two heart failure-digitalis patients. All patients had blood counts, serum electrolyte levels, renal function studies, chest roentgenograms, echocardiograms, and electrocardiograms obtained. All patients were in stable normal sinus rhythm and had normal electrolytes and blood counts.
The normal subjects were healthy based upon a medical history and physical examination. Moreover, these subjects had normal cardiac function by echocardiography and were not receiving any medication.
All studies were performed in the supine, postabsorptive state. Informed, written consent was obtained from all subjects before study, and the protocol was approved by the Human Subjects Review Committee of the University of Iowa.
Measurements in Heart Failure Patients
On the morning of study, the heart failure patients were taken to the cardiac catheterization laboratory for complete resting hemodynamic assessment. A 7.5F flow-directed oximetry thermodilution SwanGanz catheter (American Edwards Laboratories, Santa Ana, California) was inserted percutaneously under local anesthesia (1% lidocaine, <5 ml) into either the left subclavian or right internal jugular veins through an indwelling 8F sheath. A 4F polyethylene arterial catheter was placed percutaneously under local anesthesia into the right brachial artery.
Resting hemodynamic assessment included systemic arterial and right heart pressures. Serial rightsided oxygen saturation samples were obtained, and these excluded an intracardiac left-to-right shunt in all patients. Thermodilution cardiac output was determined with 10-ml iced-saline injections (five measurements) with a SAT-1 Oximeter/Cardiac Output Computer (American Edwards Laboratories), and simultaneous Fick cardiac output was determined by measuring oxygen consumption with a Metabolic Rate Meter (MRM, Waters Instruments, Rochester, Minnesota) and obtaining blood samples for arterial-mixed venous oxygen content difference.
The patients were transferred to the Clinical Cardiovascular Physiology Laboratory in the Cardiovascular Intensive Care Unit for the investigational protocol. During further studies, pulmonary artery diastolic pressure was considered as the measurement of left heart filling pressure because initial assessment determined excellent correlation (r=0.98, p<0.001) between pulmonary artery diastolic pressure and pulmonary capillary wedge pressure. Cardiac output was subsequently measured by thermodilution because of an excellent correla- 
Protocol
Studies were begun after a 20-minute rest period during which all subjects were familiarized with the experimental techniques. Control measurements of hemodynamics and MSNA were obtained during a continuous 5-minute period, and cardiac output was determined each minute. After this, the subjects received either Cedilanid-D (0.02 mg/kg), placebo (normal saline), or dobutamine (3.4±0.4 gg/kg/ min). The Cedilanid-D (heart failure-digitalis and normal subject-digitalis groups) or placebo was administered intravenously during 5 minutes, whereas the dobutamine was infused continuously. Dobutamine infusion (heart failure-dobutamine group) was titrated to achieve the same percent increase in pulmonary artery oxygen saturation (assessed continuously with a fiberoptic Swan-Ganz catheter27,28) as was achieved after administration of Cedilanid-D to the other heart failure patients. Beginning 20 minutes after onset of drug administration, a second continuous 5-minute period of hemodynamic and MSNA recordings was obtained.
Statistical Analysis
The mean values for hemodynamic and MSNA variables during the 5-minute periods before (control) and after drug administration were compared within each group by paired t tests. Comparison of control variables between the digitalis and dobutamine heart failure groups was performed by unpaired t tests as were the absolute and percent changes in variables between two different treatment groups. Correlation between Fick and thermodilution cardiac output determinations and between pulmonary capillary wedge and pulmonary artery diastolic pressures were performed by linear regression analysis. Statistical significance was considered asp less than 0.05. Values are presented as mean±SEM.
Results
Patient and Nornal Subject Groups
The clinical and demographic characteristics of the digitalis and dobutamine heart failure groups are summarized in Table 1 effect of time or vehicle on hemodynamics and MSNA. These patients were all men, aged 39, 47, and 51 years, and had left ventricular ejection fractions of 21%, 16%, and 34%, respectively. Cardiac enlargement in these patients was similar to that in the other heart failure patients with left ventricular end-diastolic diameters of 6.5+0.4 cm and left atrial diameters of 4.5 +0.4 cm. The causes of cardiac impairment were idiopathic cardiomyopathy (n = 1) and ischemic heart disease secondary to prior anterior infarction (n =2).
Resting Hemodynamic Indexes in Heart Failure Groups Table 2 summarizes the resting hemodynamic indexes obtained in the cardiac catheterization laboratory for the heart failure patients in the digitalis and dobutamine treatment groups. There were no significant differences between the two groups in resting arterial pressure, heart rate, cardiac index, arterial-mixed venous oxygen content difference, or systemic or pulmonic vascular resistance. The dobutamine group had lower pulmonary artery pressures.
Responses of Heart Failure Patients to Short-term Administration of Digitalis Table 3 and Figure 1 show the hemodynamic and MSNA effects of Cedilanid-D in the eight heart and total MSNA activity (from 784.7±143.5 to 416.0±103.6 units/min,p<0.01). This represented a 51±8% attenuation of MSNA. The change in sympathetic traffic could not be accounted for by the decrease in heart rate. When total integrated MSNA was expressed as units per 100 heart beats, Cedilanid-D reduced MSNA from 831.0±118.4 to 474.4±103.6 units/100 heart beats (p<0.01). Thus, Cedilanid-D decreased MSNA whether expressed as bursts/min, units/min, or units/100 heart beats. Figure 2 presents portions of recordings of hemodynamics and MSNA from subject 4 before (control) and 23 minutes after administration of Cedilanid-D. There was an increase in cardiac output and pulse pressure, a decrease in cardiac filling pressures, and a slowing of heart rate after administration of the digitalis glycoside. This patient showed significant forearm vasodilation and substantial sympathoinhibition after short-term administration of digitalis.
Effects of Time and Placebo in Heart Failure Patients
Placebo (5% dextrose in water) was administered to three additional patients with milder heart failure in a fashion identical to that used for Cedilanid-D to assess the effects of time and vehicle on hemodynamics and MSNA. Placebo had no effect on resting levels of any hemodynamic or MSNA value. Placebo did not alter forearm vascular resistance (from 21.3 ±0.6 to 22.0 ±2.7 units,p=NS) or MSNA (from 29 20 .9±3.0 bursts/min, p<O.O1). However, unlike the responses of the heart failure patients, this response appeared to be due to changes in heart rate because there was no significant change in the level of sympathetic activity when corrected for associated changes in heart rate (from 494.8±88.5 to 369.1±60.5 units/100 heart beats, p=NS). This preservation of MSNA in these normal subjects occurred despite significant increases in arterial systolic, mean, and pulse pressures.
Responses of Heart Failure Patients to
Dobutamine
The heart failure-dobutamine patients had immediate predrug hemodynamic indexes that were not statistically different from those of the heart failuredigitalis patients (Tables 3 and 4 , control values), although cardiac filling pressures tended to be lower in the dobutamine group. Table 4 and Figure 4 show the hemodynamic and MSNA effects of intravenous infusion of dobutamine to the seven heart failuredobutamine patients.
Dobutamine produced no statistically significant changes in arterial systolic, diastolic, mean, or pulse pressures or heart rate. Dobutamine resulted in an increase in cardiac index (+34+3%,p<0.01) that was comparable to the 23±7% increase produced by Cedilanid-D administration (p=NS, dobutamine vs. Cedilanid-D) and was confirmed by an increase in pulmonary artery oxygen saturation (+12±4%, p<0.01). Dobutamine produced a decrease in pulmonary artery diastolic (-28±5%, p<0.01) and right atrial (-63±11%,p<0.001) pressures. There was no significant change in forearm blood flow or forearm vascular resistance during dobutamine infusion.
Despite significant inotropic effects of dobutamine, MSNA was not altered in these patients when expressed as burst frequency (from 42.1±8.0 to 39.4±8.3 bursts/min,p=NS), total activity (from 448.7±96.0 to 406.7±88.2 units/min, p=NS), or when activity was corrected for changes in heart rate (from 527.6±112.7 to 443.7±95.9 units/100 heart beats, p= NS).
Discussion
Using direct recordings of efferent sympathetic nerve activity to muscle, we compared the autonomic effects of short-term administration of digitalis in patients with heart failure and in normal subjects. To determine the mechanism of the observed effects of digitalis, we examined the autonomic effects of the nondigitalis inotropic agent dobutamine in a similar group of heart failure patients. From these studies, we conclude that 1) digitalis glycosides produce profound sympathoinhibition and peripheral vasodilation in patients with moderate-to-severe heart failure, 2) the sympathoinhibitory effects of digitalis in heart failure most likely cannot be ascribed solely to an inotropic action because similar inotropic doses of dobutamine failed to attenuate MSNA in a second group of heart failure patients, and 3) in normal humans, increase in arterial pressure after digitalis administration does not produce the expected degree of sympathoinhibition, suggesting a possible sympathoexcitatory action of the agent.
The discussion focuses on the 1) mechanisms of sympathoinhibitory effect of digitalis in heart failure patients, 2) mechanisms of sympathoexcitatory action of digitalis in normal humans, 3) We considered four potential mechanisms to explain the net inhibitory action of digitalis on MSNA in these patients: 1) direct activation of sinoaortic baroreceptors by the increase in arterial pressure, 2) direct activation of cardiopulmonary baroreceptors by the inotropic effect of Cedilanid-D, 3) a centrally mediated inhibitory action, and 4) a sensitization of afferent baroreceptor mechanisms due to direct membrane actions of digitalis.
Systemic arterial pressure regulation is critically dependent upon reflex responses to alterations in arterial transmural pressure sensed by mechanoreceptors located in the walls of the great vessels. 29 The primary determinants of the activity of these receptors include both phasic and static blood pressure variables, including systolic, mean, diastolic, and pulse pressures. In the present studies, digitalis produced modest increases in arterial systolic and pulse pressures without significant change in mean or diastolic pressures in the heart failure patients. Previous studies of normal humans in our laboratory show that modest phenylephrine-induced increases in arterial pressure, similar in magnitude to those observed in the present studies, are accompanied by marked decreases in MSNA. 22 Although experimental30 and clinical31-34 studies suggest that heart disease is associated with impairment of arterial baroreflexes, this is best documented for control of heart rate. Therefore, at least part of the sympathoinhibitory action of digitalis in the heart failure patients reported here may be due to mechanical activation of afferent arterial baroreflex mechanisms.
We considered the possibility that the inotropic action of digitalis may attenuate MSNA by mechanical stimulation of tonically active cardiopulmonary baroreceptors that exert inhibitory restraint on the brainstem cardiovascular centers. Prior studies show that positive inotropic agents (i.e., sympathomimetic amines) can augment and that negative inotropic agents (i.e., ,B-adrenoceptor blocking agents) can attenuate the influence of ventricular baroreceptors in animals34-36 and humans.19,2' Recent studies of patients with severe heart failure with intracoronary administration of the noncatecholamine, nondigitalis, inotropic agent milrinone also suggest that inotropic influences can produce reflex sympathetic inhibition, although the effect appears to be relatively minor.37 However, our observations of the effect of dobutamine on MSNA in the second group of heart failure patients argue strongly that an inotropic effect alone cannot be the sole mechanism responsible for the digitalis-induced attenuation of MSNA. Despite administration of doses of dobutamine that produced similar inotropic effects to that seen with Cedilanid-D (Tables 3 and 4) , dobutamine failed to alter sympathetic nerve traffic.
We considered the possibility that the tendency for lower baseline levels of cardiac filling pressures and MSNA in the dobutamine-treated patients, compared with the Cedilanid-D-treated patients, may account for the different effects on MSNA observed after inotrope administration. However, as shown in Table 3 for the heart failure-digitalis group, both patients with high resting levels of MSNA (i.e., patients 1 and 4) and those with lower levels of resting MSNA (i.e., patients 5 and 7) had significant attenuation of MSNA after Cedilanid-D administration. In addition, as shown in Table 4 for the heart failure-dobutamine group, even patients with severe low-output states (i.e., patients 2 and 7) who received dobutamine failed to show substantial decreases in MSNA. Part Thames and colleagues8 showed an augmentation of the depressant effects of volume loading or coronary occlusion on reflex control of renal sympathetic nerve activity in dogs after intracoronary administration of acetylstrophanthidin. Recent studies in humans by Ferrari et a141 showed that intravenous administration of a rapidly acting digitalis preparation significantly increases the bradycardic and hypotensive responses to carotid baroreceptor stimulation. Most recently, Lopez and colleagues42 suggested that the net effects of digitalis glycosides on vascular and autonomic responses reflect a dosedependent relation. In these canine studies, intracarotid injection of low doses of ouabain produced a peripheral vasodilatory response that was abolished by carotid sinus denervation. However, injection of higher doses of ouabain produced a peripheral vasoconstrictor response that was not abolished by carotid sinus denervation. These studies suggest that the net effect of digitalis administration may reflect both baroreflex-mediated sympathoinhibitory responses and centrally mediated sympathoexcitatory mechanisms.
Although not precisely quantitated during the present studies, attenuation of MSNA by Cedilanid-D in the heart failure patients appeared to be an early phenomenon, preceding any observable hemodynamic effects such as changes in blood pressure, cardiac filling pressures, or pulmonary artery oxygen saturation (an indirect assessment of cardiac output). Thus, at least some of the sympathoinhibition produced by digitalis may have resulted from nonmechanical activation of afferent baroreflex mechanisms. This effect is presumably due to sensitization of tonically active, inhibitory low-or high-pressure baroreceptors. Such a mechanism of action is also supported by prior observations from our laboratory that administration of rapidly acting digitalis glycosides rapidly normalizes baroreflexmediated vascular responses to simulated orthostatic stress in patients with heart failure.19
Mechanisms of Sympathoexcitatory Action of Digitalis in Nornal Humans
As did Mason Therefore, we do not believe that the small decrease in cardiac filling pressures alone can explain the preservation of MSNA in these subjects.
Animal studies suggest that central neural sites are important in influencing peripheral effects of digitalis glycosides. The central nervous system plays an important role in the genesis of digitalisinduced cardiac arrhythmias.38,43 Spinal transection studies44 and brainstem stimulation studies45 have defined the area postrema as a likely site for this central neural mediation of the arrhythmogenic effects of digitalis glycosides. This area of the lower brainstem is rich in vascular supply, lacking in normal blood-brain barrier properties, and has been identified as the site of the emetic effects of digitalis.46 Brainstem stimulation studies,47 cerebral cross perfusion studies,14 and studies with highly polar digitalis glycosides,47 which do not cross the normal blood-brain barrier, have also identified the area postrema as a site mediating the coronary vasoconstricting effects of digitalis glycosides. This vasoconstrictor effect occurs because of an efferent a-adrenergic mechanism.13 Electri-cal stimulation of the area postrema produces an increase in systemic vascular resistance. 48 Because this area of the central nervous system connects with descending autonomic pathways,49 it may be an important site of the sympathoexcitatory effects of digitalis observed in our studies.
Clinical Implications
The studies reported here have examined early responses to short-term administration of a rapidly acting digitalis glycoside to patients with moderateto-severe heart failure. As such, these studies provide only limited direct clinical implications. As shown in these studies, rapidly acting digitalis produces a prompt inotropic effect in patients with significant heart failure. The early inotropic effect achieved is comparable to that elicited with low doses of dobutamine. In contrast to dobutamine, however, the inotropic effect of Cedilanid-D was associated with an attenuation of efferent sympathetic nerve activity and a decrease in forearm vascular resistance, although total systemic resistance was unchanged. Whether or not these vasodilatory and sympathoinhibitory effects of digitalis are sustained will need to be addressed in future long-term studies. Recent experimental studies by Thames et a150 show that long-term administration of digoxin to dogs produces sustained sensitization of inhibitory vagal afferents. It is intriguing to speculate that such a sympathoinhibitory effect may be beneficial in patients with heart failure, a disorder known to be associated with marked neurocirculatory excitation.19,51-54 Potential Limitations of Studies
We recognize several potential limitations in the design and interpretation of these studies. First, these studies examined the short-term effects of short-term administration of digitalis in both the heart failure patients and normal subjects. It is possible that the effects of long-term administration of digitalis will be different. In animals, however, long-term administration of digitalis produces sustained sensitization of inhibitory vagal afferents.50 Prospective, placebo-controlled trials will be required to assess the long-term autonomic effects of digitalis in patients with heart failure.
A second limitation is that we have been required to base our conclusions on measurements of reflex changes in the efferent limb of the baroreflex (MSNA, heart rate, forearm vascular resistance) rather than on direct assessment of afferent nerve signals from baroreceptors. Nevertheless, prior human studies in our laboratory showed convincingly that changes in heart rate and MSNA closely parallel perturbation of arterial baroreceptors22,55 alone, and changes in MSNA parallel perturbation of cardiopulmonary baroreceptors alone23 by either pharmacologic or mechanical means.
A third potential limitation of these studies is that experiments performed in intact humans are subject to the limitations of studying a "closed-loop" physiologic preparation. In such a closed-loop system, the response to an experimental stimulus may, in turn, influence the stimulus itself. However, this possibility cannot explain our finding of different autonomic responses to the administration of the same agent (digitalis) in the heart failure patients and to the normal subjects.
A fourth consideration in the interpretation of these studies is that we used sympathetic nerve recordings from only one site, the peroneal nerve, and measurements of blood flow from only the forearm. Differences are known to exist in the control of sympathetic nerve activity to various tissues and vascular beds.25,56 Nonetheless, in normal subjects, spontaneously occurring fluctuations in MSNA are similar in different extremity sites.57 Furthermore, the changes in forearm vascular resistance during these studies were in most cases accompanied by parallel changes in MSNA. In these studies, all intraindividual MSNA responses were compared with a stable control recording of MSNA. Thus, although we cannot generalize to total or other organ-specific sympathetic responses, the intraindividual comparisons of peroneal MSNA responses remain valid.
